Novo Nordisk inaugurates Latin America's largest insulin plant in Brazil
Novo Nordisk has inaugurated a major expansion of its production facilities in Montes Claros, Brazil. The new plant, which is the largest manufacturing facility of Novo Nordisk outside Denmark, represents an investment of approximately US$200m. This is the largest single investment in the history of the pharmaceutical industry in Brazil.
Novo Nordisk has inaugurated a major expansion of its production facilities in Montes Claros, Brazil. The new plant, which is the largest manufacturing facility of Novo Nordisk outside Denmark, represents an investment of approximately US$200m. This is the largest single investment in the history of the pharmaceutical industry in Brazil.
'Today, we are not just inaugurating a new factory. We are celebrating one of the most significant milestones in the history of Novo Nordisk as an international company. The new Montes Claros facility is a cornerstone in the company's global operations and reflects our commitment to the Brazilian market,' says Lars Rebien Sorensen, president and ceo of Novo Nordisk.
The new plant contains the most advanced insulin formulation and filling technology available in the world. With the opening of the new plant, the company will have almost doubled the number of employees in Montes Claros from 400 to 750 employees by the end of 2007.
The new unit will increase Novo Nordisk's insulin manufacturing capacity in Brazil significantly. The plant will formulate and fill insulin into 3ml Penfill cartridges, which are used in the pen systems marketed by Novo Nordisk.